FibroBiologics, Inc. FBLG
NASDAQ · United States · Health Technology
$1.24+0.03 (+2.90%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office has granted European Patent No. 3568465, titled "Methods of Enhancing Fibroblast Therapeutic Activity." The patent covers methods of augmenting the efficacy of fi
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
ORLANDO, FL / ACCESS Newswire / September 25, 2026 / RedChip Companies will air interviews with Nova Minerals Corp (NYSE American:NVA)(ASX:NVA) and FibroBiologics, Inc. (NASDAQ:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, September 26, at 7:00 p.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.